Biogen Idec Inc. (BIIB)

Index: Nasdaq 100
-0.00%
-$0.01
$313.97
23:26 17/11/17
$313.97
23:26 17/11/17
DAILY VARIATION
-0.00%
-$0.01
VOLUME
826,600
DATA
52 Week High
$344.58
52 Week Low
$246.54
Shares Issued
211.43m
Market Cap
$66,383.23m
RiskGrade
116
Beta
0.93
MENU

Biogen Idec Inc. Overview

In November 2003, Biogen and IDEC Pharmaceuticals finalised their $6bn merger, creating Biogen Idec, the third-largest biotechnology company in the world. The company is now a global leader in the development, manufacturing, and commercialisation of novel therapies. Its major products include treatments for relapsing multiple sclerosis, certain B-cell non-Hodgkin's lymphomas and adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Intraday Chart

Historic Charts

Latest F'cast
Div Yield n/a 0.0%
Div Cover n/a n/a
Op Mrgn n/a 50.9%
ROCE n/a
Latest F'cast
P/E n/a 1,407.3
PEG n/a 1.5
Pr/Revenue n/a 5.5
Pr/Book n/a
Latest F'cast
Revenue 40.0% 0.8%
PBT 59.1% n/a
EPS 58.0% 6.0%
DPS n/a 0.0%

Key Fundamentals

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2012-12-31 5,516.46 1,859.62 580.00¢ 25.2 1.8 14% n/a 0.0%
2013-12-31 6,932.20 2,480.58 786.00¢ 35.6 1.0 36% n/a 0.0%
2014-12-31 9,703.32 3,946.63 1,242.00¢ 27.3 0.5 58% n/a 0.0%

Forecast

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2016-12-31 11,448.80 5,876.40 2,022.00c 1,535.3 24.4 63% 0.00c 0.0%
2017-12-31 12,014.30 6,110.97 2,208.09c 1,407.3 152.9 9% 0.00c 0.0%
2018-12-31 12,604.84 6,578.39 2,375.06c 1,318.2 174.3 8% 0.00c 0.0%

Regulatory News

No results found

Newspaper Links

No results found